<DOC>
	<DOCNO>NCT00993148</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy novel combination antiretroviral therapy regimen consist maraviroc plus darunavir/ritonavir treatment-naive patient infected R5-tropic HIV-1 . The hypothesis treatment-naive subject infect R5-tropic HIV-1 , combination antiretroviral therapy maraviroc plus darunavir/ritonavir well tolerate efficacious .</brief_summary>
	<brief_title>Maraviroc Plus Darunavir/Ritonavir Treatment-Naïve Patients Infected With R5-tropic HIV-1</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>HIV1 infection , document licensed HIV test kit confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA time prior study entry Plasma HIV1 RNA 5 , 000 500,000 copies/mL obtain within 90 day prior study entry Exclusive R5 tropism base enhanced sensitivity Trofile assay do within 90 day prior entry CD4 cell count &gt; 100 cells/mm3 within 90 day prior study entry HIV genotype ( RT protease ) perform time study entry ( Subjects single combination NNRTI NRTI RAM ( ) screening permit ) ARV drugnaïve , define previous ARV treatment time prior study entry Negative result hepatitis B surface antigen test perform within 90 day prior study entry Negative result hepatitis C antibody test perform within 90 day prior study entry Laboratory value obtain within 30 day prior study entry : ANC &gt; =750/mm3 Hemoglobin &gt; =10 g/dL Platelets &gt; =50,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; =5 x ULN Calculated creatinine clearance ( CrCl ) &gt; =30 mL/min , estimate CockcroftGault equation* Negative serum urine pregnancy test within 48 hour prior study entry woman reproductive potential If participate sexual activity could lead pregnancy , study subject reproductive potential must use one form contraceptive receive protocolspecified medication 60 day stop medication . Men woman age &gt; =18 year Ability willingness subject legal guardian/representative provide inform consent Serious illness require systemic treatment and/or hospitalization candidate either completes therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry Screening HIV genotype obtain time prior study entry DRV RAM ( V11I , V32I , L33F , I47V , I50V , I54L , I54M , T74P , L76V , I84V , L89V ) Treatment within 30 day prior study entry immune modulators systemic steroid , interleukin , interferon , granulocyte colonystimulating factor ( GCSF ) , erythropoietin , investigational therapy . NOTE : Subjects receive stable physiologic glucocorticoid dos ( define prednisone ≤10 mg/day [ equivalent ] stable taper dose ) permit . Subjects receive corticosteroid acute therapy PCP asthma exacerbation , receive short course ( defined ≤2 week pharmacologic glucocorticoid therapy ) permit Breastfeeding Requirement medication prohibit study medication Known allergy/sensitivity study drug formulation . A history sulfa allergy exclusion Active drug alcohol use dependence could interfere adherence study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Treatment naive</keyword>
</DOC>